

DGI-023



OPTIMAL

MISSED 5 MISSED 3 DOSES DOSES

MISSED 2 DOSES MISSED 1

# Description of omalizumab use for the treatment of asthma after four years of experience

L. Serrano De Lucas, A. Bustinza Txertudi, B. Baza Martínez, S. Sautua Larreategui, A. De Basagoiti Gorordo, I. Bilbao Meseguer, A. Belaustegui Foronda, Z. Baskaran Kaltzakorta, J. Hernández Goicoechea, E. Rodríguez España

Hospital Universitario Cruces, Pharmacy Department, Barakaldo (Spain) laura.serranodelucas@osakidetza.net


## Background

Omalizumab's labelled indication is the treatment of IgE mediated asthma. It was approved for its use in our hospital in 2008. In 2011 it became necessary to develop a protocol which clarified patient selection and treatment withholding criteria.

# Objectives

To describe the patients treated with omalizumab, focusing on whether they match our protocol's usage criteria or not.

### **Methods**



• Previous asthma therapy included montelukast or theophylline in 19 patients (61%).

Basal IgE was below 76 UI/mL in one patient.

• 13 patients had no pre-treatment hospitalizations nor emergency department visits.

### Conclusion

Our patients still need to be selected better, although most of the protocol discrepancies correspond to patients who started before the protocol was implemented.

The protocol requirement with less compliance was the emergency department use.